An observational study in Critically Ill, Acute Respiratory Failure and Acute Heart Failure, sponsored by Australian and New Zealand Intensive Care Research Centre. Recruiting at 29 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-15.
Sponsored by Australian and New Zealand Intensive Care Research Centre · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Heart Arrest with a site in Australia — 3 open to participants now, 5 under way, 1 of them phase 3. Heart Arrest · Australia.
Among the 14 studies in Heart Arrest with a site in Australia, this one is one of 2 that started in 2019, is one of 5 observational ones, and was the 11th registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →3 of the 14 studies in Heart Arrest with a site in Australia are open now. Recruiting first, the newest first:
Australian and New Zealand Intensive Care Research Centre · Sites in Australia
Healthy volunteers
Children's Hospital of Philadelphia · Sites in Australia, United States, Brazil and 12 more countries
Ages 0–18
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2019.
This study's planned enrollment of 3,000 is above the median of 200 across 376 observational studies indexed under Heart Arrest.
Median enrollment 600 across the 9 interventional studies, 1,820 across the 5 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 14 have an industry lead sponsor. The 10 most frequent:
Australian and New Zealand Intensive Care Research Centre is the lead sponsor of 49 studies on the registry; 16 are open to participants now.
Australian and New Zealand Intensive Care Research Centre has 3 studies filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
2 of the studies in Heart Arrest with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07579390Helsinki University Central HospitalEffects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE) | 2026-12 |
| NCT03793257Australian and New Zealand Intensive Care Research CentreThe EXCEL Registry of Patients Requiring ECMO | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Heart Arrest with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
ECMO is associated with significant costs, risks and requires specialist training and expertise. EXCEL is a novel, high-quality, detailed prospective registry of patients requiring ECMO in Australia and New Zealand. The registry provides information on patient selection, complications, costs and patient reported outcome measures. EXCEL uses the Theoretical Domains Framework to identify evidence-practice gaps and explore barriers and enablers to tailor implementation of evidence
The aim of EXCEL is to generate a bi-national multidisciplinary network of integrated care for patients suffering acute cardiac or respiratory failure or cardiac arrest requiring extracorporeal membrane oxygenation (ECMO) to monitor long term outcomes and identify best practice.
Each year around 130,000 Australians and New Zealanders are admitted to an intensive care unit (ICU). The sickest patients in the ICU who have severe failure of the heart or lungs may require an external machine to oxygenate their blood in addition to a mechanical ventilator. This intervention, called extracorporeal membrane oxygenation (ECMO), involves circulating all of the patient's blood through large cannulae to external machinery every minute. It has the capability of completely replacing a non-functioning heart or lungs for days to weeks on end. These critically ill patients who require ECMO are the sickest in the hospital with only 42% hospital survival. The use of ECMO has doubled in Australia and New Zealand and globally over five years, and in the USA has increased by 433%.
The use of ECMO is associated with significant costs and risks, and it requires specialist training and expertise. In order to prepare for the organisation of these complex interventions in the ICU across regions, the investigators need to have accurate data on patients undergoing ECMO. The investigators monitor and review current practice in ECMO services by providing robust binational registry data to service providers and clinicians with a closed-loop feedback system. EXCEL explores barriers and enablers to evidence-based care in ECMO services and providing a platform to embed clinical trials. The investigators will translate findings with greater capacity, reach, and impact to drive measureable change in practice and improve patient-centred outcomes.
The EXCEL Partnership represents a novel, coordinated effort to create a high-quality, detailed, prospective registry of patients requiring ECMO at ECMO centres. A tailored, detailed ECMO registry (EXCEL) can be used to address specific safety concerns, clinical questions and process of care issues. As a result, EXCEL can be designed and implemented to answer new investigator-initiated, hypothesis-driven clinical questions.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
This study's planned enrollment of 3,000 is above the median of 200 across 376 observational studies indexed under Heart Arrest.
Browse Heart Arrest studies →Australian and New Zealand Intensive Care Research Centre is the lead sponsor of 49 studies on the registry; 16 are open to participants now.
Compared within Heart Arrest, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients admitted to hospitals with a primary diagnosis of acute heart failure, respiratory failure or cardiac arrest and received ECMO at participating ECMO centres.
Inclusion Criteria:
Nil Exclusion Criteria
Disability-free survival at 6 months, defined as alive and free of disability, measured with the World Health Organisation's Disability Assessment Schedule (WHODAS 2.0) score of <25%.
WHODAS 2.0 measured using a trained, blinded assessor via telephone interview. The WHODAS scores are calculated using the sum of the six domain scores. These domain scores are then converted to a metric score ranging from 0 to 100 (where 0= no disability; 100= full disability)
Time frame: At 6 months from study enrolment
Number of participants with adverse events including major bleeding up to 28 days after ECMO, infection, thrombosis (in the ECMO cannulae or in the patient) and limb ischaemia
All adverse events are recorded determined by treating clinician
Time frame: Up to 28 days after ECMO initiation
Healthcare utilization - caseload per centre
ECMO patient numbers (caseload per centre)
Time frame: Up to 12 months from study enrolment
Healthcare utilization - ECMO initiation timing
Timing of ECMO initiation by staff including an ECMO retrieval team
Time frame: Up to 12 months from study enrolment
Healthcare utilization - number of staff members required to manage ECMO
Staff numbers required for the provision of ECMO in ICU and the training required for these staff members to perform their role.
Time frame: Up to 12 months from study enrolment
Healthcare utilization - hospital length of stay
Hospital and in-patient rehabilitation length of stay including hospital readmissions and time spent in ICU
Time frame: Up to 12 months from study enrolment
Healthcare costs
Number of resources including staff and, equipment and blood products utilised whilst the patient was receiving hospital care until 6 months following hospital admission.
Time frame: Measured from ECMO commencement to hospital discharge until 6 months following hopsital admission.
Health-related quality of life at baseline, 6 and 12 months using the EQ5D-5L
Measured using the EQ5D-5L, delivered by a trained, blinded assessor via telephone interview. The EQ5D includes an analogue scale that asks the patient to rate their health on a scale of 0 to 100. (Where 0= worst health imaginable; 100= best health imaginable)
Time frame: At 6 and 12 months from study enrolment. Retrospective baseline measured at 6 months.
Number of patients with disability at 6 and 12 months
Measured using the WHODAS 2.0, delivered by a trained, blinded assessor via telephone interview
Time frame: At 6 and 12 months from study enrolment
Psychological function at 12 months
Measured using the EQ5D-5L, delivered by a trained, blinded assessor via telephone interview
Time frame: At 12 months from study enrolment
Return to work at 6 months
Return to work measured bu the WHODAS 2.0, delivered by a trained, blinded assessor via telephone interview
Time frame: At 6 months from study enrolment
Disability at baseline, 6 and 12 months
Patient reported disability using a disability scale, delivered by a trained, blinded assessor via telephone interview
Time frame: Measured at 6 and 12 months. Retrospective baseline disability measured at 6 months.
Activities of daily living at 6 and 12 months
Activities of daily living measured at 6 and 12 month using the ADL and IADL, delivered by a trained, blinded assessor via telephone interview
Time frame: Measured at 6 and 12 months
Cognitive function at 12 months
Cognitive function measured at 12 months using the MOCA Blind, delivered by a trained, blinded assessor via telephone interview
Time frame: Measured at 12 months
Number patients who survive to 12 months following ECMO initiation
Measured by Research Coordinators at each of the participating sites
Time frame: At 12 months from study enrolment
Not enrolling at this site — choose another above.
Started Feb 2019 (actual). Primary completion is estimated for Dec 2026, 94 months after the start.
Of 169 non-industry observational studies under Heart Arrest, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 94 months is above that.
Counting every sponsor, half of 176 studies reached it within 41 months; a quarter within 18 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Australian and New Zealand Intensive Care Research Centre